Comment on "Drug survival analysis is not a good method for assessing the safety or effectiveness of systemic therapies in psoriasis"
- PMID: 28504083
- DOI: 10.1016/j.ad.2017.03.012
Comment on "Drug survival analysis is not a good method for assessing the safety or effectiveness of systemic therapies in psoriasis"
Comment in
-
Response to the Comment by Van den Reek et al. on Drug Survival Analysis is not a Good Method for Assessing the Safety or Effectiveness of Systemic Therapies in Psoriasis.Actas Dermosifiliogr. 2017 Sep;108(7):697-698. doi: 10.1016/j.ad.2017.03.011. Epub 2017 May 12. Actas Dermosifiliogr. 2017. PMID: 28504087 English, Spanish. No abstract available.
Comment on
-
Drug Survival Analysis Is Not a Good Method for Assessing the Safety or Effectiveness of Systemic Therapies in Psoriasis.Actas Dermosifiliogr. 2017 Jan-Feb;108(1):3-5. doi: 10.1016/j.ad.2016.09.001. Epub 2016 Oct 17. Actas Dermosifiliogr. 2017. PMID: 27765164 English, Spanish. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
